Timber pharmaceuticals announces nyse acceptance of plan to regain listing compliance

Warren, nj, sept. 18, 2023 (globe newswire) -- via newmediawire – timber pharmaceuticals, inc. ("timber" or the “company”) (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the nyse american llc (the “nyse american”) has accepted the company's business plan to regain compliance with the continued listing standards set forth in sections 1003(a)(i) and (ii) of the nyse american company guide.
TMBR Ratings Summary
TMBR Quant Ranking